Sign In
Buy CDNA
$38.37
-1.36 (-3.42%)
At Close: Jul 20, 2026
CareDx, Inc. (CDNA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
04:38pm, Monday, 08'th Jun 2026
CareDx, Inc. (CDNA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Baron Discovery Fund Q1 2026: Who Moved The Needle
01:35am, Monday, 08'th Jun 2026
In the first quarter of 2026, Baron Discovery Fund declined 10.65% (Institutional Shares), trailing the Russell 2000 Growth Index by 7.84% due to significant underperformance in the software sector. A
CareDx Highlights 39% Q1 Growth, Naveris Oncology Push at Jefferies
06:04am, Sunday, 07'th Jun 2026
CareDx NASDAQ: CDNA executives outlined the company's growth strategy, first-quarter performance and pipeline priorities during a presentation at the Jefferies Healthcare Conference, emphasizing trans
CareDx to Participate in Upcoming Investor Conferences
04:01pm, Wednesday, 20'th May 2026
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clini
CareDx Announces Dismissal of 2021 Qui Tam Suit
04:05pm, Monday, 11'th May 2026
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clini
CareDx, Inc. (CDNA) Q1 2026 Earnings Call Transcript
07:43am, Monday, 04'th May 2026
CareDx, Inc. (CDNA) Q1 2026 Earnings Call Transcript
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 01'st May 2026
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of c
CareDx (CDNA) Q1 Earnings and Revenues Top Estimates
06:48pm, Tuesday, 28'th Apr 2026
CareDx (CDNA) came out with quarterly earnings of $0.34 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.09 per share a year ago.
CareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing
04:05pm, Tuesday, 28'th Apr 2026
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clini
CareDx Announces First Quarter 2026 Financial Results
04:01pm, Tuesday, 28'th Apr 2026
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clini
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clini
CareDx Launches AlloSeq Nano for High-Resolution Rapid HLA Typing
12:42pm, Tuesday, 21'st Apr 2026
CDNA unveils AlloSeq Nano, delivering high-resolution HLA typing in under 3 hours, aiming to boost transplant diagnostics speed and lab efficiency.
CareDx Introduces AlloSeq Nano at EFI 2026, Expanding HLA Typing Portfolio with Long-Read Sequencing
07:05am, Monday, 20'th Apr 2026
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clini
All You Need to Know About CareDx (CDNA) Rating Upgrade to Buy
01:00pm, Friday, 17'th Apr 2026
CareDx (CDNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
CareDx Sharpens Focus On Core Testing Services
02:37pm, Thursday, 16'th Apr 2026
The transaction, approved by both companies' boards, is expected to close by the end of the third quarter of 2026.
